-

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 14th, at 9:30 a.m. PST (12:30 p.m. EST), followed by a question and answer session at 10:00 a.m. PST (1:00 p.m. EST). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.

A live webcast of the presentation and the subsequent question and answer session will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for approximately two weeks.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Contacts

Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

Charles River Laboratories International, Inc.

NYSE:CRL

Release Summary
Charles River Laboratories to present at the J.P. Morgan Healthcare Conference
Release Versions
$Cashtags

Contacts

Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

More News From Charles River Laboratories International, Inc.

Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Launched in December 2024, with the inaugural cohort announced in April 2025, the program provides early-stage biotechnology pioneers with access to extensive scientific and commercial expertise, as well as a comprehensive ecosystem of discovery, development, and manufacturing capabilities, to expedite the develo...

Charles River Laboratories to Present at Evercore Healthcare Conference

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Evercore Healthcare Conference...

Charles River Laboratories to Present at Jefferies Global Healthcare Conference

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Jefferies Global Healthcare Conference...
Back to Newsroom